-
Ribociclib, Acid Reduction, and pH-Mediated Absorption
2026-08-26
Desai and colleagues combined an Analytical Quality by Design framework with a biorelevant micro-dissolution model to examine whether physiological pH shifts could alter ribociclib succinate solubility in the presence of acid-reducing therapy. Although solubility decreased after gastric and intestinal pH transitions, the authors concluded that the changes were unlikely to produce a clinically meaningful absorption interaction, while emphasizing the value of this workflow for early formulation and drug-interaction risk assessment.
-
Honokiol N1672 for Reliable Cell Assays
2026-08-26
Learn how Honokiol (SKU N1672) can help researchers separate cytostasis from cell death, control solvent and stability variables, and interpret viability data more rigorously. This scenario-based guide combines product specifications with evidence on in vitro drug-response measurement.
-
SLC25A1, Senescence, and Cisplatin Resistance in HNSCC
2026-08-25
The reference study identifies SLC25A1 as a regulator of cisplatin resistance in head and neck squamous cell carcinoma, linking mitochondrial citrate transport to H3K27ac-dependent transcription and cellular senescence. Its findings position SLC25A1 as both a candidate biomarker and a therapeutic target, while also emphasizing the need to interpret β-galactosidase readouts within a broader senescence assay framework.
-
CIH, Gut Microbiota, and Mitochondrial Apoptosis
2026-08-25
This 2026 study connects chronic intermittent hypoxia with lung apoptosis through coordinated changes in gut microbiota, fatty-acid metabolism, and mitochondrial fission. Its combined microbiome, metabolomics, histological, and pharmacological design suggests that DRP1-dependent mitochondrial injury is a mechanistic node linking intestinal and pulmonary responses to CIH.
-
SGI-1027 DNA Methyltransferase Inhibitor Workflows
2026-08-24
SGI-1027 is a DNA methyltransferase inhibitor for connecting DNMT activity, promoter methylation, tumor suppressor gene reactivation, and cancer-cell response in one experimental design. Its strongest use-case is not a single viability endpoint, but a layered workflow that separates growth arrest from cell death while confirming epigenetic mechanism.
-
Intravesical p21 mRNA–LNP Therapy for Bladder Cancer
2026-08-24
This 2026 FASEB Journal study developed chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21 expression, disrupted tumor-cell proliferation, and suppressed orthotopic tumor growth while producing predominantly bladder-localized protein expression in mice.
-
Angiotensin II: Redox Logic in Vascular Assays
2026-08-23
Angiotensin II is more than a vasoconstrictor: it is a controllable probe of receptor-driven redox signaling, VEGF induction, and vascular remodeling. This guide translates the LOX-1–dependent angiogenesis study into practical assay decisions for mechanistic vascular research.
-
(+)-Bicuculline Protocol and QC Guide
2026-08-22
(+)-Bicuculline is a research reagent for controlled blockade of GABAA-mediated inhibitory signaling, with applications in synaptic physiology and neuronal signaling assays. This guide covers solubility, storage, controls, and troubleshooting; the compound is for scientific research only and must not be used for diagnosis, treatment, or clinical decision-making.
-
Cholesterol in mRNA-LNP Workflows
2026-08-22
Learn how to use Cholesterol as a controlled formulation variable for lipid nanoparticle, membrane, and lipid metabolism experiments. This practical guide connects cholesterol handling and assay design with localized p21 mRNA-LNP delivery research while clearly separating published findings from workflow recommendations.
-
MRT68921: Rethinking ULK1 Control in Autophagy
2026-08-21
A thought-leadership guide to using MRT68921 as a mechanistic ULK1/2 perturbation tool, with emphasis on AMPK–ULK1 biology, ATG13 phosphorylation blockade, LC3 flux measurement, experimental controls, translational maturity, and study design limitations.
-
CDELNs Relieve Sertoli-Cell Cycle Arrest
2026-08-20
This reference study identifies Cistanche deserticola exosome-like nanovesicles (CDELNs) as a plant-derived intervention for cyclophosphamide-induced testicular injury. Its central mechanistic finding is that CDELN-delivered miR159b-3p targets P21, promotes CDK1 activation, and alleviates cell-cycle arrest in Sertoli cells, with human single-cell transcriptomic data providing translational context.
-
PGE2 Workflows for Inflammation Research
2026-08-20
Build reproducible Prostaglandin E2 assays for receptor pharmacology, inflammatory cell models, and biomaterial screening. This practical guide connects PGE2 exposure design with the stimulus-responsive hydrogel strategy reported for intervertebral disc degeneration.
-
15-PGDH Inhibition Supports Muscle Repair During Weight Loss
2026-08-19
A 2026 PNAS study identifies 15-PGDH inhibition as a way to improve muscle stem cell activity, regenerated myofiber growth, and force recovery during semaglutide-associated weight loss in obese mice. The findings suggest that combining a GLP-1 receptor agonist with a 15-PGDH inhibitor may improve postinjury muscle quality without eliminating the desired reduction in body weight.
-
Of Chloroquine and COVID-19: Evidence in Context
2026-08-19
Touret and de Lamballerie’s commentary examined early enthusiasm for Chloroquine against SARS-CoV-2 through the broader history of antiviral research. Its central contribution was to distinguish reproducible in vitro activity from animal and clinical efficacy, while highlighting how immune modulation can produce unexpected outcomes.
-
20-HETE–TRPV1 Signaling in Chronic Dermatitis
2026-08-18
The reference study identifies a peripheral mechanism for allokinesis, showing that elevated 20-HETE activates TRPV1 on sensitized MrgprA3+ sensory neurons in chronic dermatitis. Its combination of behavioral genetics, electrophysiology, metabolomics, and pharmacological inhibition connects lesional lipid metabolism to itch–pain conversion and suggests a testable route for pathway-specific intervention.